Cat. No. 4872
Chemical Name: 4-[Bis(1,3-benzodioxol-5-yl)hydroxy
Biological ActivityHighly selective and potent monoacylglycerol lipase (MAGL) inhibitor. Exhibits potent inhibition of human, mouse and rat MAGL (IC50 values are 5.9, 15 and 43 nM, respectively). Exhibits no detectable inhibition of FAAH (IC50 > 50000 nM). Potently and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50 = 2.5 nM and >50 μM for 2-AG and AEA respectively).
Licensing InformationSold under license from The Scripps Research Institute
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Chang et al (2012) Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem.Biol. 19 579. PMID: 22542104.
Ueda et al (2012) Discrimination between two endocannabinoids. Chem.Biol. 19 545. PMID: 22633404.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for KML 29 include:
Morena et al (2016) Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. Neuropharmacology 111 59. PMID: 27553121.
Do you know of a great paper that uses KML 29 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: KML 29, supplier, KML29, MAGL, inhibitor, MAG, lipase, monoacylglycerol, lipase, inhibitors, MGL, endocannabinoids, 2, AG, arachidonoylethanolamide, anandamide, inhibits, Tocris Bioscience, Monoacylglycerol Lipase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective poly (ADP ribose) glycohydrolase (PARG) inhibitor; cell permeableJZP 361
Potent and selective reversible MAGL inhibitorURB 602
Non-competitive MAGL inhibitor(S)-Crizotinib
April 22 - 26, 2017
Chicago, IL, USA